THE DEAL, AT A GLANCE
From the announcementMonte Rosa Therapeutics
01Who is involvedBacked by VariousFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedMonte Rosa Therapeutics raised $150M Growth RoundFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03Why it mattersMonte Rosa Therapeutics is using $150M in Growth Round financing to advance AI-designed molecular glue degraders for oncology, with MRT-2359 positioned as a MYC degrader…From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Monte Rosa Therapeutics · Financing Record
Explore source-linked visual explanations for Monte Rosa Therapeutics. Unsupported claims are withheld while source review continues.
Record 1120 · Recorded date: Needs review
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →